FASN and fatty liver disease: In contrast, pharmacological inhibition of FASN in leptin receptor–deficient (db/db) mice ameliorated fed hyperglycemia, but not hepatic steatosis, in association with a reduction in food intake and BW gain, with these findings having cast doubt on the liver specificity of the drug action (31, 32).